Equip Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual eating disorder treatment using family-based therapy, San Diego CA, raised $58M+. First at-home model for anorexia and bulimia treatment in the US.
About
Equip Health is a San Diego, California-based virtual care company founded in 2019 that specializes in treating eating disorders including anorexia, bulimia, binge eating disorder, and avoidant restrictive food intake disorder (ARFID). The company has raised over $58 million and has pioneered a virtual delivery model for family-based treatment (FBT), the gold-standard evidence-based therapy for adolescent eating disorders, making intensive evidence-based care accessible outside of residential treatment programs.\n\nEquip's care model assembles a five-person care team for each patient: a therapist, a dietitian, a physician, a family mentor, and a peer mentor — all coordinating through the platform. This team-based virtual approach mirrors the multidisciplinary structure of leading eating disorder treatment centers while eliminating the geographic and financial barriers that prevent most patients from accessing residential care. Sessions are conducted by video with the patient and their family, with meal support and between-session coaching embedded in the program.\n\nThe company distributes its services through insurance coverage, accepting major commercial plans and working to expand Medicaid coverage. Eating disorders carry the highest mortality rate of any psychiatric illness, yet treatment access is severely limited in the United States. Equip's virtual model has treated patients across all 50 states, demonstrating the feasibility of delivering intensive eating disorder care at home and positioning the company as a national provider in a historically fragmented specialty.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.